Investigating the Potential of Cuboidal Nanometals as Protein Subunit Vaccine Carriers In Vivo
Source abstract
Abstract
Abstract Metal nanoparticles (NPs) are suggested as a vaccine delivery platform. At present, there is limited description of cuboidal Ag nanocubes (AgNCs; nonporous) and Au nanocages (AuNCs; porous) as a protein carrier for vaccination. Here, the intrinsic protein binding ability of AgNC and AuNC is first investigated, using ovalbumin (OVA) as a model antigen, to determine its suitability as a vaccine carrier. Next, the effect of AgNCs and AuNCs on bone‐marrow‐derived dendritic cells (BMDCs) is assessed in vitro. Finally, in vivo humoral and cellular immune responses of AgNC–OVA and AuNC–OVA following intramuscular immunization and their prophylactic effects in B16F10‐OVA mice tumor model are investigated. In terms of OVA loading efficiency, AgNCs are superior to AuNCs. Both nanomaterials are found not to induce BMDC maturation at subtoxic doses. After administration of nanovaccines, serum immunoglobulin G (IgG) responses are comparable between groups. However, there are slight alterations in relative frequencies of lymphocyte subpopulations, with AgNC–OVA‐immunized mice exhibiting lower memory T cells and reduced B cell and T follicular helper cell populations in spleen. Overall, AgNC–OVA and AuNC–OVA immunizations do not alter tumor growth. This study characterizes the intrinsic immunomodulatory properties of AgNCs and AuNCs, as protein subunit vaccine carriers.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmaceutical Science Faculty of Life Sciences & Medicine King's College London Franklin‐Wilkins Building, 150 Stamford Street London SE1 9NH UK
Advanced Technology Research and Application Center Selcuk University Aleaddin Keykubat Yerleskesi, Akademi Mah. Yeni Istanbul Cad. No: 355/C, Selcuklu Konya 42130 Turkey
Funding
British Council · Wellcome Trust
References (61)
Show source-provided references
1. 10.1039/C6SC03631G10.1039/C6SC03631G ↗
2. 10.3389/fimmu.2019.0050010.3389/fimmu.2019.00500 ↗
3. Neto L. M. M. · Hum. Vaccines Immunother. · 2018 · 14 · 2786
4. 10.1016/j.addr.2023.11482910.1016/j.addr.2023.114829 ↗
5. 10.1021/acs.nanolett.9b0283410.1021/acs.nanolett.9b02834 ↗
6. 10.1016/j.actbio.2018.08.01110.1016/j.actbio.2018.08.011 ↗
7. 10.1007/s13205-020-02573-y10.1007/s13205-020-02573-y ↗
8. 10.1016/j.ccr.2021.21434510.1016/j.ccr.2021.214345 ↗
9. 10.1016/j.ddtec.2021.02.00110.1016/j.ddtec.2021.02.001 ↗
10. 10.1016/j.biomaterials.2019.01.03410.1016/j.biomaterials.2019.01.034 ↗
11. 10.2147/IJN.S13722210.2147/IJN.S137222 ↗
12. 10.1088/0957-4484/21/19/19510110.1088/0957-4484/21/19/195101 ↗
13. 10.1371/journal.pone.024188210.1371/journal.pone.0241882 ↗
14. 10.1016/j.drudis.2021.03.00710.1016/j.drudis.2021.03.007 ↗
15. 10.1002/smll.20120152810.1002/smll.201201528 ↗
16. 10.1007/s10529-020-02853-w10.1007/s10529-020-02853-w ↗
17. 10.1021/nn305700510.1021/nn3057005 ↗
18. 10.1039/C8BM01272E10.1039/C8BM01272E ↗
19. 10.7150/jca.1156710.7150/jca.11567 ↗
20. He J.‐s. · Front. Pharmacol. · 2021 · 12
21. 10.1039/D0SC05146B10.1039/D0SC05146B ↗
22. 10.1021/nn203124x10.1021/nn203124x ↗
23. 10.1016/j.msec.2021.11208610.1016/j.msec.2021.112086 ↗
24. 10.1016/j.actbio.2022.01.05110.1016/j.actbio.2022.01.051 ↗
25. 10.7150/thno.2763110.7150/thno.27631 ↗
26. 10.1038/nmat256410.1038/nmat2564 ↗
27. 10.1016/j.biomaterials.2017.09.02910.1016/j.biomaterials.2017.09.029 ↗
28. 10.1016/j.nano.2021.10235810.1016/j.nano.2021.102358 ↗
29. 10.1007/s12034-021-02487-210.1007/s12034-021-02487-2 ↗
30. 10.3390/v1010052410.3390/v10100524 ↗
31. 10.3390/nano1104096410.3390/nano11040964 ↗
32. 10.1016/j.biomaterials.2019.11930810.1016/j.biomaterials.2019.119308 ↗
33. 10.1002/wnan.170710.1002/wnan.1707 ↗
34. 10.1038/nprot.2007.32610.1038/nprot.2007.326 ↗
35. 10.1021/ja300901e10.1021/ja300901e ↗
36. 10.1021/acsnano.1c0486210.1021/acsnano.1c04862 ↗
37. 10.1016/j.vaccine.2018.09.03010.1016/j.vaccine.2018.09.030 ↗
38. 10.1016/j.colsurfb.2017.09.04610.1016/j.colsurfb.2017.09.046 ↗
39. 10.1016/j.colsurfb.2012.07.03610.1016/j.colsurfb.2012.07.036 ↗
40. 10.1021/acsnano.3c0092010.1021/acsnano.3c00920 ↗
41. 10.3390/polym1316272610.3390/polym13162726 ↗
42. 10.1039/c3tb21526a10.1039/c3tb21526a ↗
43. 10.1038/s41467-017-01175-210.1038/s41467-017-01175-2 ↗
44. 10.1038/nbt134010.1038/nbt1340 ↗
45. 10.7150/thno.536910.7150/thno.5369 ↗
46. 10.1016/j.toxlet.2013.09.02010.1016/j.toxlet.2013.09.020 ↗
47. 10.1021/nn304332s10.1021/nn304332s ↗
48. 10.1016/j.molimm.2017.09.00110.1016/j.molimm.2017.09.001 ↗
49. 10.3390/cells1001009610.3390/cells10010096 ↗
50. 10.1021/acsnano.5b0771610.1021/acsnano.5b07716 ↗
51. 10.1016/j.toxlet.2013.02.01010.1016/j.toxlet.2013.02.010 ↗
52. 10.1021/nl300027p10.1021/nl300027p ↗
53. 10.1007/s11051-009-9692-010.1007/s11051-009-9692-0 ↗
54. 10.1080/1547691X.2019.158465210.1080/1547691X.2019.1584652 ↗
55. 10.1371/journal.pone.009658410.1371/journal.pone.0096584 ↗
56. 10.1021/bc500467u10.1021/bc500467u ↗
57. 10.1016/j.celrep.2021.10959110.1016/j.celrep.2021.109591 ↗
58. 10.1021/acs.nanolett.0c0253610.1021/acs.nanolett.0c02536 ↗
59. 10.1186/s12979-019-0162-y10.1186/s12979-019-0162-y ↗
60. 10.1111/1348-0421.1275410.1111/1348-0421.12754 ↗
61. Liu X. · Bio‐Protoc. · 2015 · 5